Publications by the researcher in collaboration with Ramón Colomer Bosch (8)

2022

  1. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

    Nature Communications, Vol. 13, Núm. 1

2020

  1. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

    Breast Cancer Research, Vol. 22, Núm. 1

2018

  1. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

    Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 815-826

  2. Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia

  3. Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology (Clinical and Translational Oncology, (2018), 20, 7, (815-826), 10.1007/s12094-017-1800-5)

    Clinical and Translational Oncology

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. Critically short telomeres and toxicity of chemotherapy in early breast cancer

    Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482

2010

  1. Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated

    Journal of Clinical Oncology, Vol. 28, Núm. 6, pp. 960-966